The The Prothena Corporation PLC (PRTA) Receives $76.00 Average PT from Analysts

Prothena Corp

Prothena PLC (PRTA) Reaches $64.69 After 6.00% Up Move; Portland General Electric Co Has 1.38 Sentiment

Evercore ISI assumed coverage on shares of Prothena Corporation PLC in a research note on Wednesday, August 16th. Wedbush maintained the stock with "Outperform" rating in Friday, February 19 report. Ameritas Investment Partners Inc. bought a new stake in Prothena Corporation PLC in the first quarter valued at $167,000. Jefferies Group LLC began coverage on shares of Prothena Corporation PLC in a research report on Monday, July 10th. Deutsche Bank initiated it with "Buy" rating and $73 target in Thursday, November 3 report. Oppenheimer Holdings, Inc. set a $70.00 target price on shares of Prothena Corporation PLC and gave the stock a buy rating in a research report on Thursday, May 11th. Prothena Corp had 18 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Prothena Corporation PLC (NASDAQ:PRTA) earned "Buy" rating by Suntrust Robinson on Wednesday, December 21. The company has an average rating of Buy and an average price target of $78.31. Prothena Corporation PLC (NDAQ:PRTA) has risen 41.05% since September 16, 2016 and is uptrending. Moreover, Central Securities Corp has 2.26% invested in the company for 310,000 shares. Finally, Wellington Management Group LLP lifted its stake in shares of Prothena Corporation PLC by 4.6% during the 1st quarter. The company has market cap of $2.44 billion.

The stock last traded at $62.74 which is just a bit higher than the 50 day moving average of $59.39 and which is quite a bit above the 200 day moving average of $56.18.

Florida Keys residents trickle back to warning of new crisis
Trump never made clear if he knew how many lives had been lost in Irma, and he said nothing else recognizing the victims. Rick Scott is doing such a good job with the recovery effort that he should run for the Senate.

The stock of Prothena Corporation PLC (NASDAQ:PRTA) earned "Overweight" rating by Barclays Capital on Friday, May 13. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.89) by $0.43.

Wall Street await Prothena Corporation PLC (NASDAQ:PRTA) to release earnings on November, 7. The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $5.35 million. During the same period in the prior year, the business posted ($1.18) earnings per share. Teacher Retirement System of Texas increased its position in shares of Prothena Corporation PLC by 14.0% in the second quarter. Analysts anticipate that Prothena Corporation PLC will post ($4.39) EPS for the current fiscal year. BTIG Research began coverage on shares of Prothena Corporation PLC in a report on Friday, May 19th. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and worldwide trademark & copyright law. The correct version of this news story can be read at The shares were sold on July 17th for an average price of $64.64. Following the completion of the transaction, the director now owns 6,345 shares in the company, valued at $368,707.95. Evercore Wealth Mngmt Limited Liability owns 4 shares or 0% of their USA portfolio. Also, insider Karin L. Walker sold 5,000 shares of the firm's stock in a transaction dated Monday, July 17th. Volume was down 37.43% under the stocks average daily volume. Walker now owns $0 of stock as recorded in a recent Form 4 SEC filing. The disclosure for this sale can be found here.

Possible American citizen fighting for ISIS surrenders, Pentagon says
Foreign fighters captured in Iraq have been held by the Iraqi military, which has said it would try them. Suspects accused of terror-related offenses, including Americans, also can be adjudicated in USA courts.

A number of research analysts recently weighed in on PRTA shares. Prothena Corporation PLC's quarterly revenue was down 35.5% compared to the same quarter past year. As of quarter end Opaleye Management Inc. had disposed of a total of 2,100 shares trimming its holdings by 2.4%. Emerald Acquisition Ltd. acquired a new position in shares of Prothena Corporation PLC during the second quarter valued at about $195,000. OMERS ADMINISTRATION Corp now owns 5,000 shares of the biotechnology company's stock worth $271,000 after purchasing an additional 100 shares during the period. Insiders own 3.70% of the company's stock. Bank of Montreal Can increased its stake in Prothena Corporation PLC by 6.7% in the second quarter. The value of the company's investment in Prothena Corporation plc - Ordi went from $4,859,000 to $4,600,000 decreasing 5.3% quarter over quarter.

Prothena Corporation Public Limited Company, launched on September 26, 2012, is a global biotechnology company. The Firm is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody product candidates targets a range of indications, including Amyloid Light-chain amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Pakistan will waste time by raising Kashmir issue in UNGA
A day earlier, Pakistan's Foreign Ministry had said that PM Abbasi would be raising the Kashmir issue at the UN. He said, "Pakistan has not formally raised Kashmir issue at United Nations in the last 40 years".

Latest News